Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

cg or 15mcg of sufentanil. Doses were delivered sublingually as needed to treat pain with a 20-minute minimum re-dosing interval and patients were allowed to drop out of the study at any time. Positive results were also obtained for the primary endpoint following treatment with the 15mcg dose compared to placebo using two alternate methods for imputing missing data from drop-outs: baseline observation carried forward (BOCF), p = 0.007, and last observation carried forward (LOCF), p = 0.018. Importantly, there were no events of clinically significant respiratory depression for any dosing group. Based on these positive results, AcelRx intends to further advance clinical development of ARX-01 in 2009.

"We are pleased by the wonderful clinical results of our Phase 2 post-operative acute pain study," said Thomas A. Schreck, chairman and chief executive officer of AcelRx Pharmaceuticals. "This is the culmination of a great deal of hard work by a team of efficient, dedicated people over the last two years, and is therefore very gratifying indeed. This trial has the benefit of validating Sublingual Sufentanil NanoTabs as a robust product candidate for its initial in-hospital acute pain indication, as well as providing the foundation of safety and efficacy for the other programs in our pipeline."

About ARX-01 Sublingual Sufentanil NanoTabs

Sufentanil is currently approved as an intravenous (IV) anesthetic and is also indicated for epidural administration during labor and delivery. Due to their small size, ARX-01 Sublingual Sufentanil NanoTabs are convenient, well-tolerated, have high bioavailability and provide lower peak plasma levels compared to IV administration.

About the ARX-01 Oral Patient-Controlled Analgesia System

The ARX-01 Oral Patient-Controlled Analgesia (PCA) system is based on a proprietary pre-programmed, hand-held dispenser being developed by AcelRx. The AcelRx d
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger researcher ... nominated for a Centers for Disease Control and Prevention ... major public health concern. Joseph Boscarino ... one of a team of researchers nominated for the ... Shepard Science Award for Data Methods and Study Design. ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... , , SANTA CLARA, Calif., Sept. 8 ... Board: APNO) today announced that they have entered into a ... Cell Biosciences for $1.50 per share or approximately $17.9 million ... analysis business to include a global infrastructure and a broad ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, ... pharmaceutical company with its principal operations in the People,s,Republic ... year 2009. The Company expects to meet or ... and operating income of $40 to $43 million for ...
... , , ... systems biology tools company, announced today that Proteostasis Therapeutics has ... Therapeutics is the first company dedicated to the discovery of ... Network. The Proteostasis Network maintains the body,s natural balance ...
Cached Biology Technology:Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2GeneGo Licenses MetaCore to Proteostasis Therapeutics 2
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
(Date:8/20/2014)... acral melanomas the rare type of skin cancer that ... from other more common types of skin cancer, according to ... Pigment Cell & Melanoma Research . , Acral melanoma most ... feet, nail-beds and other hairless parts of the skin. Unlike ... UV damage from the sun. , The team, from the ...
(Date:8/20/2014)... During the past few years, Virginia Tech,s Wu Feng ... Microsoft grant from the "Computing in the Cloud" program, ... a $6 million award from the Air Force on ... from NSF and the National Institutes of Health on ... wove together the "parallel computing" aspects from each grant, ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... 2008) A new study by the Bronx Zoo-based ... the Greater Yellowstone Ecosystem have apparently hopped into oblivion. ... of the journal Oryx, also speculates that the disappearance ... a variety of other prey species and their predators. ...
... crucial proteins in our bodies must fold into complex shapes ... to move them around, to speed up important chemical reactions ... "off" to affect which proteins our cells make. Recently, ... genetic code into protein-can act a lot like a protein ...
... of shrimp and fish in tropical coastal areas is ... poverty, but in fact this cultivation has negative consequences ... Daniel A. Bergquist of Uppsala University, Sweden, has studied ... The cultivating of fish and shellfish in artificial ...
Cached Biology News:Hareless: Yellowstone's rabbits have vanished, study says 2Stanford researchers make first direct observation of 3-D molecule folding in real time 2Stanford researchers make first direct observation of 3-D molecule folding in real time 3Stanford researchers make first direct observation of 3-D molecule folding in real time 4Stanford researchers make first direct observation of 3-D molecule folding in real time 5Global trade in tiger shrimp threatens environment 2
... Ultrapure ACS Reagent Grade C 19 ... Formula Weight: 691.95 PRODUCT SPECIFICATIONS Form: Powder ... Interval: pH 3.0 - Yellow ... a tracking dye in agarose and acrylamide ...
... reads and processes raw microarray ... data for analysis. ,Package ... 1-year license for Feature Extraction ... CD-ROM containing Feature Extraction software ...
... Feature Extraction Software reads and ... to prepare microarray data for ... one 1-year license for ... accounts , * one ...
... 4 H 10 O 2 S ... SPECIFICATIONS Form: White crystalline powder Assay: ... Identity: By IR Melting Point: greater ... DTT: less than or equal to ...
Biology Products: